Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Quoin Pharmaceuticals  / Equity Bottom-Up

<ul><li> There are no approved NS treatments currently & Quoin is optimistic that QRX003 can become the first.</li><li>The overall patient population is fairly sizable QNRX estimates there are ~6k-7k patients in the U.S. and EU.</li><li>Moreover, NS is often undiagnosed.</li></ul>

 There are no approved NS treatments currently & Quoin is optimistic that QRX003 can become the first.The overall patient population is fairly sizable QNRX estimates there are ~6k-7k patients in the U.S. and EU.Moreover, NS is often undiagnosed.

QNRX: More Positive Data Supporting Efficacy of QRX003 for NS  Campaign to Raise Awareness of the Disease